Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life through its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform, capable of making a wide variety of edits (delete, insert, excise) to an organism's genomic DNA. The company leverages ARCUS to develop a pipeline of allogeneic CAR T immunotherapy and in vivo gene editing therapies for cancer and genetic diseases. Their approach aims to overcome limitations of other gene editing technologies by offering unique DNA cutting, high specificity, and broad editing capabilities.
The headquarters serves as the central node for all company operations, including research and development, clinical trial management, corporate strategy, and administrative functions. It also houses their state-of-the-art Manufacturing Center for Cures (MCC).
Key features include advanced laboratory spaces for gene editing research, process development, and analytical capabilities, alongside the cGMP-compliant Manufacturing Center for Cures (MCC) designed for clinical-scale manufacturing of cell and gene therapies.
The work culture at Precision BioSciences is characterized by scientific rigor, innovation, and collaboration. Employees are driven by a shared mission to develop groundbreaking therapies for patients with unmet medical needs, fostering an environment of intellectual curiosity and dedication.
The Durham headquarters is pivotal to Precision BioSciences' success, concentrating its core scientific talent, technological infrastructure, and manufacturing capabilities, enabling seamless progression from discovery to clinical development.
While Precision BioSciences is headquartered and primarily operates from Durham, NC, USA, its strategic collaborations, clinical trials, and the potential reach of its therapeutic candidates give it a global footprint. The company engages with the international scientific community and aims to develop therapies for patients worldwide.
302 E. Pettigrew St., Suite A-100
Durham
North Carolina
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, PrecisionBI' leadership includes:
PrecisionBI has been backed by several prominent investors over the years, including:
Over the past 12 months, Precision BioSciences has made strategic additions and role transitions within its executive team to support its growth and focus on advancing its pipeline. Key appointments have strengthened financial leadership and human resources, alongside evolving technology leadership.
Discover the tools PrecisionBI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Precision BioSciences likely employs standard corporate email address formats. The most common patterns are typically [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com].
[first_initial][last]@precisionbiosciences.com
Format
jdoe@precisionbiosciences.com
Example
85%
Success rate
Precision BioSciences Press Release • May 30, 2024
Precision BioSciences announced that the first patient has been dosed in the Phase 1 multicenter clinical study of azercabtagene zapreleucel (azer-cel), an allogeneic CAR T therapy candidate for patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL)....more
Precision BioSciences Press Release • May 9, 2024
The company reported its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical programs and ARCUS platform advancements, highlighting progress with its in vivo gene editing programs and CAR T therapies....more
Precision BioSciences Press Release • May 7, 2024
Precision BioSciences presented new preclinical data showcasing the capabilities of its ARCUS gene editing platform, including advancements in gene insertion and delivery technologies, at the ASGCT 2024 annual meeting....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including PrecisionBI, are just a search away.